Abiraterone Acetate-d4

Abiraterone acetate-d₄ is intended for use as an internal standard for the quantification of abiraterone acetate by GC- or LC-MS. Abiraterone acetate is an inhibitor of the cytochrome P450 (CYP) isoform CYP17A1 (IC₅₀s = 17 and 18 nM for inhibition of C_17,20-lyase and 17α-hydroxylase activities, respectively).¹ It is also a prodrug form of abiraterone .² Abiraterone acetate reduces plasma testosterone levels, increases plasma luteinizing hormone levels, and reduces ventral prostate, seminal vesicle, testis, and kidney weight in mice when administered at doses of 0.1 and 0.5 mmol/kg per day. It also reduces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in the culture supernatant of infected Vero E6 cells (EC₉₀ = 8.4 μM) and is active in a plaque reduction assay (EC₅₀ = 1.94 μM).³ Formulations containing abiraterone acetate have been used in combination therapy for the treatment of metastatic castration-resistant prostate cancer.

1.Potter, G.A., Barrie, S.E., Jarman, M., et al.Novel steroidal inhibitors of human cytochrome P45017α (17α-hydroxylase-C17,20-lyase): Potential agents for the treatment of prostatic cancerJ. Med. Chem.38(13)2463-2471(1995) 2.Barrie, S.E., Potter, G.A., Goddard, P.M., et al.Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17-20 lyase)J. Steroid Biochem. Mol. Biol.50(5-6)267-273(1994) 3.Yuan, S., Chan, J.F.W., Chik, K.K.H., et al.Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening systemPharmacol. Res.159104960(2020)